Active-ingredient Dossier
Mometasone Furoate
Active-ingredient Dossier for Mometasone Furoate (topical corticosteroid). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: RYALTRIS
- Brand: ENERZAIR BREEZHALER
- Brand: ATECTURA BREEZHALER
- Brand: ELOCON
- Brand: GLENMARK
- Brand: NOVASONE
- Therapeutic area: Respiratory
- Therapeutic area: Dermatology
- Therapeutic area: Immunology
What is
Mometasone Furoate Mometasone furoate is a topical corticosteroid.
Australian brands containing
Mometasone Furoate — RYALTRIS — ATECTURA BREEZHALER — ELOCON — ENERZAIR BREEZHALER — GLENMARK — NASONEX — NOVASONE — ZATAMIL
Therapeutic areas
Mometasone furoate is registered across multiple therapeutic areas: respiratory (6 brands), dermatology (4 brands), infectious disease (3 brands), and immunology (1 brand).
Sponsor landscape
The ingredient is marketed by nine sponsors, including Organon Pharma, Bayer, Novartis Pharmaceuticals, Sandoz, Arrotex Pharmaceuticals, and Grand Medical.
PBS and regulatory activity
One brand has a PBAC outcome on record, with the latest assessment dated 1 July 2020. Two brands have AusPARs on record, with the latest dated 28 January 2022.